History in Brief
Dyax was co-founded in 1995 by biotechnology entrepreneur Henry E. Blair, who served as director and Chief Executive Officer until 2008, when his executive role was transitioned to Gustav Christensen. Mr. Blair continues to serve Dyax as Chairman of the Board.
Dyax was formed by the merger of Biotage, a separations instrument chromatography firm, and Protein Engineering Corporation, from which we acquired our patented phage display technology. In 2003, we sold Biotage in order to focus exclusively on the discovery and development of biotherapeutics.
Dyax completed its initial public offering (IPO) in August 2000 and is listed on the NASDAQ exchange (Ticker: DYAX). Since becoming a public company, we have continued to evolve as a biopharmaceutical company. Now, we have two main business elements.
The first element is focused on the development and commercialization of treatments for angioedemas that are identified as plasma kallikrein (bradykinin) mediated, including hereditary angioedema (HAE). We developed KALBITOR® (ecallantide) on our own and are currently selling it in the United States for the treatment of acute attacks of HAE.
The second element is focused on our proprietary phage display technology, which we leverage through our Licensing and Funded Research Program, referred to as the LFRP. This program has provided Dyax a portfolio of product candidates being developed by its licensees, which includes a large number of product candidates in various stages of clinical development, including several in Phase 3 trials.